Series A financing co-led by Sofinnova Partners and RA Capital alongside founding investor Oxford Science Enterprises with support from Cancer Research Horizons and the University of Oxford, bringing together a world-class transatlantic syndicate

A轮融资由Sofinnova Partners和RA Capital联合领投，创始投资者牛津科学企业（Oxford Science Enterprises）跟投，并得到Cancer Research Horizons和牛津大学的支持，汇聚了一支世界级的跨大西洋投资联盟。

Proceeds will fund the Phase 1/2a studies needed to progress ATX-011, a first-in-class therapy for essential thrombocythaemia (ET) and advance additional MPN programmes toward IND submission

所得资金将用于资助推进ATX-011（一种针对原发性血小板增多症[ET]的首创疗法）所需的1/2a期临床研究，并推动其他骨髓增殖性肿瘤（MPN）项目向新药临床试验申请（IND）提交迈进。

ATX-011 binds a novel target with potential for broad therapeutic benefit irrespective of driver mutation

ATX-011 结合一个新型靶点，具有广泛的潜在治疗益处，且不受驱动突变的影响

Preclinical data for ATX-011 has been selected for oral presentation at the American Society of Hematology (ASH) 2026 Annual Meeting

ATX-011 的临床前数据入选美国血液学会（ASH）2026 年年会口头报告

Oxford, United Kingdom

牛津，英国

– 5 November 2026 – Alethio Therapeutics ('Alethio'), a biopharmaceutical company developing next-generation therapies for myeloproliferative neoplasms (MPNs), today announces the successful completion of an oversubscribed $90 million (£67 million) Series A financing.

– 2026年11月5日 – Alethio Therapeutics（“Alethio”）是一家致力于开发骨髓增殖性肿瘤（MPNs）下一代疗法的生物制药公司，今日宣布成功完成一轮超额认购的9,000万美元（6,700万英镑）A轮融资。

The substantial round was co-led by new investors Sofinnova Partners and RA Capital, alongside founding investor Oxford Science Enterprises, with additional support from Cancer Research Horizons and the University of Oxford. In conjunction with the financing, Graziano Seghezzi, Managing Partner at Sofinnova Partners, and Maxwell DeNies from RA Capital have been appointed to Alethio’s Board of Directors..

本轮大额融资由新投资者 Sofinnova Partners 和 RA Capital 联合领投，创始投资者 Oxford Science Enterprises 参与跟投，并获得了 Cancer Research Horizons 和牛津大学的额外支持。伴随此次融资，Sofinnova Partners 的管理合伙人 Graziano Seghezzi 以及 RA Capital 的 Maxwell DeNies 已获委任加入 Alethio 董事会。

The proceeds of the financing will enable Alethio to transition into a clinical-stage company, with capital deployed to advance its lead programme, ATX-011, through completion of Phase 1/2a studies in essential thrombocythaemia (ET), up to Phase 3 readiness, while also progressing additional MPN programmes towards IND submission..

此次融资所得将使Alethio转型为一家临床阶段公司，资金将用于推进其核心项目ATX-011，完成针对原发性血小板增多症（ET）的1/2a期临床研究，直至具备开展3期临床试验的条件，同时推动其他骨髓增殖性肿瘤（MPN）项目向新药临床试验申请（IND）提交迈进。

“Too often, a patient's first encounter with ET is a thrombotic event that lands them in the emergency room,” said

“患者与原发性血小板增多症（ET）的初次接触往往是一场使其被送入急诊室的血栓事件，”

Dr Rohit Batta, Chief Executive Officer

首席执行官罗希特·巴塔博士

of Alethio Therapeutics

Alethio Therapeutics 的

. “What follows is typically lifelong treatment with therapies that can cause burdensome side effects and are associated with high rates of resistance. Alethio was founded on a simple conviction - if you can selectively eliminate the cells driving disease, you can redefine what is possible for patients.

“接下来的治疗通常是终身的，所用的疗法可能带来沉重的副作用，并且耐药率很高。Alethio 的创立基于一个简单的信念——如果能够选择性地清除驱动疾病的细胞，就能重新定义患者治疗的可能性。”

This financing enables us to turn that conviction into reality.”.

这笔融资使我们能够将这一信念转化为现实。

Founded as a spin-out from the University of Oxford by Professors Adam Mead and Beth Psaila, two of the world's leading physician-scientists in MPNs, Alethio is building a pipeline of novel therapies informed by their deep expertise in MPN biology. MPNs, including ET, are blood cancers characterised by the uncontrolled production of blood cells and an increased risk of thrombosis, bone marrow scarring (myelofibrosis), and transformation to acute leukaemia..

Alethio 由牛津大学分拆成立，创始人是 Adam Mead 教授和 Beth Psaila 教授，这两位是全球骨髓增殖性肿瘤（MPN）领域领先的医师科学家。依托他们在 MPN 生物学方面的深厚专业积累，Alethio 正在构建一系列新型疗法的产品管线。MPN（包括真性红细胞增多症 ET）是一类血液癌症，其特征为血细胞不受控制地生成，并伴有血栓形成、骨髓纤维化（骨髓瘢痕化）以及向急性白血病转化的风险增加。

Current therapies for ET are non-targeted treatments that have been around for decades such as hydroxycarbamide and interferon, that can affect, and disproportionately damage, healthy cells. Alethio is pursuing a different approach, developing targeted therapies designed to selectively eliminate the disease-driving cells that sustain MPNs, to modify the underlying disease features and restore healthy blood counts, reduce thrombotic risk and ultimately improve outcomes for patients..

目前，真性红细胞增多症（ET）的治疗方案多为非靶向治疗，如羟基脲和干扰素，这些疗法已沿用数十年，但会影响并 disproportionately 损害健康细胞。Alethio 正在探索一种不同的方法，开发靶向疗法，旨在选择性清除维持骨髓增殖性肿瘤（MPN）的致病驱动细胞，从而改变疾病的根本特征，恢复正常的血细胞计数，降低血栓风险，并最终改善患者预后。

Preclinical data for ATX-011 has been selected for

ATX-011 的临床前数据已被选中用于

oral presentation

口头报告

at the American Society of Hematology (ASH) 2026 Annual Meeting, underscoring the strength of Alethio's first-in-class G6B-targeting programme. ATX-011 is designed to normalise platelet counts in patients with ET by selectively enhancing platelet clearance through binding G6B, a protein expressed on platelets and megakaryocytes.

在2026年美国血液学会（ASH）年会上，突显了Alethio公司首创的靶向G6B项目的实力。ATX-011旨在通过结合血小板和巨核细胞上表达的G6B蛋白，选择性增强血小板清除，从而使原发性血小板增多症（ET）患者的血小板计数恢复正常。

Importantly, G6B is also aberrantly expressed on MPN-initiating stem cells, but not healthy stem cells, and on megakaryocytes implicated in the development of bone marrow fibrosis. These findings support the potential of ATX-011 to deliver broad therapeutic benefit across patients with MPNs irrespective of driver mutation.

重要的是，G6B在MPN起始干细胞上异常表达，而在健康干细胞上不表达；此外，G6B也在与骨髓纤维化发展相关的巨核细胞上表达。这些发现支持ATX-011有望为MPN患者带来广泛的治疗获益，无论其驱动突变类型如何。

Alethio is advancing ATX-011 through IND-enabling studies and toward clinical development in ET..

Alethio 正在推进 ATX-011 的临床试验申请（IND）支持性研究，并朝着在原发性血小板增多症（ET）中的临床开发迈进。

'The most transformative companies are built around insights that challenge long-held assumptions in medicine,' said

“最具变革性的公司往往建立在挑战医学领域长期固有认知的洞察之上，”

Graziano Seghezzi, Managing Partner at Sofinnova Partners

Graziano Seghezzi，Sofinnova Partners 的管理合伙人

. 'In MPNs, the field has long accepted that controlling the disease is enough. Alethio challenges that assumption. By targeting the cells that drive the disease, its approach has the potential to move patients beyond symptom management toward true disease modification. All of this is based on an exceptional team and founders with a deep understanding of the disease.'.

“在骨髓增殖性肿瘤（MPN）领域，长期以来人们普遍认为控制疾病已足够。Alethio 对这一假设提出了挑战。通过靶向驱动疾病的关键细胞，其治疗方法有望帮助患者超越单纯的症状管理，迈向真正的疾病修饰。这一切都基于一支卓越的团队以及创始人对疾病的深刻理解。”

'We were drawn to the strength of the biology underpinning Alethio's approach,'

“我们被Alethio方法背后强大的生物学基础所吸引，”

said Maxwell DeNies, from RA Capital.

RA Capital的Maxwell DeNies表示。

'G6B is a highly differentiated target with compelling human data supporting its role in selectively identifying disease-driving cells in MPN. Combined with the extensive patient-derived validation generated by the team, this creates a strong scientific foundation for the programme as it advances toward the clinic.'.

G6B 是一个高度差异化的靶点，拥有令人信服的人类数据支持其在骨髓增殖性肿瘤（MPN）中选择性识别致病驱动细胞的作用。结合团队所生成的广泛患者来源验证数据，这为该项目的临床推进奠定了坚实的科学基础。

'Since its formation, Alethio has made incredible progress in translating pioneering University of Oxford science into a focused and ambitious biotechnology company,' said

“自成立以来，Alethio 在将牛津大学的前沿科研成果转化为一家专注且雄心勃勃的生物技术公司方面取得了令人瞩目的进展，”

Sally Dewhurst, Principal at Oxford Science Enterprises

萨莉·杜赫斯特，牛津科学企业公司负责人

. “The team has built not only a promising lead programme but also the ARTEMIS discovery platform, providing a powerful engine for future pipeline innovation. We are proud to continue supporting the company and are delighted to welcome such an experienced syndicate to help Alethio transition to the next stage of growth; delivering meaningful impact for patients in the clinic.'.

“该团队不仅打造了一个前景广阔的主导项目，还构建了ARTEMIS发现平台，为未来产品管线的创新提供了强大的引擎。我们很荣幸能继续支持该公司，并欣喜地迎来如此经验丰富的银团，以协助Alethio过渡到下一个增长阶段，从而在临床实践中为患者带来实质性的影响。”

ENDS

结束

For further information:

更多信息：

Communications Team, Alethio Therapeutics

Alethio Therapeutics 传播团队

hello@alethiotx.com

hello@alethiotx.com

Sandi Greenwood, Frazer Hall, Mark Swallow MEDiSTRAVA

桑迪·格林伍德、弗雷泽·霍尔、马克·斯瓦洛 MEDiSTRAVA

AlethioTx@Medistrava.com

AlethioTx@Medistrava.com

About Alethio Therapeutics

关于 Alethio Therapeutics

A spin-out from the University of Oxford, Alethio Therapeutics is pioneering the development of targeted therapies with disease-modifying potential for patients with blood cancers, with the aim of helping them live fully, freely and well. The Company is focused on myeloproliferative neoplasms (MPNs), a group of chronic, incurable blood cancers where currently approved treatments are not selectively targeting disease-driving cells..

Alethio Therapeutics 是牛津大学的一家衍生公司，正率先开发具有疾病修饰潜力的靶向疗法，服务于血液癌症患者，旨在帮助他们充分、自由且健康地生活。公司专注于骨髓增殖性肿瘤（MPNs），这是一组慢性且目前无法治愈的血液癌症，而当前获批的治疗方案并未选择性靶向驱动疾病的细胞。

Alethio’s lead programme, ATX-011, is a first-in-class monoclonal antibody that targets G6B, designed to treat essential thrombocythaemia. G6B is a novel target in MPN that is uniquely expressed on MPN-initiating stem cells, but not healthy stem cells, and also expressed on megakaryocytes and platelets – the cells that drive thrombosis and transformation to myelofibrosis.

Alethio 的核心项目 ATX-011 是一款首创的单克隆抗体，靶向 G6B，旨在治疗原发性血小板增多症。G6B 是骨髓增殖性肿瘤（MPN）中的一个新颖靶点，独特地表达于 MPN 起始干细胞上，而不表达于健康干细胞；同时，它也表达于巨核细胞和血小板——这些细胞正是驱动血栓形成及向骨髓纤维化转化的关键细胞。

Alethio is advancing ATX-011 through IND-enabling studies and toward clinical development in ET..

Alethio 正在推进 ATX-011 的临床试验申请（IND）支持性研究，并推动其在真性红细胞增多症（ET）中的临床开发。

www.alethiotherapeutics.com

www.alethiotherapeutics.com

About Essential Thrombocythaemia (ET)

关于原发性血小板增多症（ET）

Essential thrombocythaemia (ET) is a myeloproliferative neoplasm characterised by excessive platelet production and an increased risk of thrombosis, bleeding, progression to myelofibrosis and transformation to acute myeloid leukaemia.¹

原发性血小板增多症（ET）是一种骨髓增殖性肿瘤，其特征为血小板过度生成，以及血栓形成、出血、进展为骨髓纤维化和转化为急性髓系白血病的风险增加。¹

Current treatments such as hydroxyurea, interferon and anagrelide focus on reducing thrombotic risk and controlling blood counts. While these therapies can control blood counts for some patients, treatment is frequently limited by tolerability challenges, skin toxicity and variable efficacy, highlighting the need for newer therapies that are targeted at the cells that drive pathology, that are better tolerated and more effectively reduce platelet counts.².

目前的 treatments 如羟基脲、干扰素和阿那格雷主要侧重于降低血栓风险和控制血细胞计数。尽管这些疗法可以在某些患者中控制血细胞计数，但治疗常因耐受性问题、皮肤毒性和疗效差异而受到限制，这凸显了对新型疗法的需求，这些疗法应针对驱动病理的细胞，具有更好的耐受性，并能更有效地降低血小板计数。²

ET represents a significant market opportunity. More than 140,000 patients are estimated to be living with the disease in the United States.³ The ET market represents a significant commercial opportunity of over $1 billion annually in the US alone.⁴

特发性震颤（ET）代表着一个巨大的市场机遇。据估计，美国有超过14万名患者患有此病。³ 仅在美国，ET市场每年的商业机会就超过10亿美元。⁴

References

参考文献

¹ Tefferi A et al.

¹ Tefferi A 等

A Review

一篇评论

. JAMA. 2025.

《美国医学会杂志》. 2025年。

² Tremblay D.  Hematology Am Soc Hematol Educ Program. 2023.

² Tremblay D. 《美国血液学会血液学教育项目》。2023年。

³ Company epidemiology analyses and market research.

³ 公司流行病学分析与市场研究。

⁴ Company market model and estimates.

⁴ 公司市场模型及估算。

Attachment

附件

Alethio Therapeutics

Alethio 治疗公司